Project information
From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
- Project Identification
- MSM0021622434
- Project Period
- 1/2007 - 12/2013
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Research Intents
- MU Faculty or unit
- Faculty of Medicine
- Keywords
- multiple myeloma; proteomics; genomics
Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.
Publications
Total number of publications: 314
2007
-
Expression of MAGE-A1 and MAGE-A3 in bone marrow from monoclonal gammapathy to myeloma patients
Year: 2007, type: Appeared in Conference without Proceedings
-
Proteomická analýza markerů rezistence buněk k bortezomibu a thalidomidu u mnohočetného myelomu
Year: 2007, type: Appeared in Conference without Proceedings
-
Two-dimensional molecular profiling of multiple myeloma
Year: 2007, type: Appeared in Conference without Proceedings
-
Využití metody stanovení volných lehkých řetězců pro časnou detekci rezistence na léčbu Velcade
Year: 2007, type: Conference abstract